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Abstract 
Intramolecular hydrogen bonding (IMHB) considerations are gaining relevance in drug discovery and a molecular 
descriptor which can predict very early the capacity of a compound to form IMHB is needed to speed up the 
optimization process of drug candidates. 
Although log Poct is largely used for optimization purposes, in this paper we firstly use the Block Relevance (BR) 
analysis to theoretically show how log Poct is not a convenient choice to assess IMHB properties of candidates. 
Then we discuss the limits of log Poct and introduce ∆log Poct-tol, i.e. the difference between log Poct and log Ptol 
(the logarithm of the partition coefficient in the toluene/water system). Finally, we provided some examples also 
including bRo5 protease inhibitors, to clarify how to interpret ∆log Poct-tol values. 
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Preface 
Lipophilicity represents the affinity of a molecule or a moiety for a lipophilic environment. It is commonly 
measured by the partition coefficient P defined as the ratio between the concentration of the solute in the 
partition solvent (immiscible with water) and its concentration in water [1]. Octanol is considered the partition 
solvent by most researchers in drug discovery thus log Poct is often simply written as log P. Here the partition 
solvent will be explicitly indicated in subscript since more solvents and thus more log Ps will be discussed in the 
paper. The second descriptor of lipophilicity is the distribution coefficient, expressed as DpH, and its logarithm 
(log DpH). It is a pH dependent descriptor for ionizable solutes and results from the weighted contributions of all 
ionised forms present at the indicated pH [1]. Since in this study we refer to neutral compounds, log Poct = 
log DpHoct all along the manuscript. 
log Poct: an established tool in drug discovery 
The role of lipophilicity descriptors in determining the overall quality of drug candidates is of paramount 
importance [2] and in fact log P is implemented in the Lipinski’s rule of five (Ro5) [3]. The Ro5 states that an orally 
active drug has no more than one violation of the following criteria: no more than 5 hydrogen bond donors (HBD, 
the total number of nitrogen–hydrogen and oxygen–hydrogen bonds), no more than 10 hydrogen bond 
acceptors (HBA, all nitrogen or oxygen atoms), a molecular mass less than 500 Daltons and a log Poct not greater 
than 5. To identify opportunities for oral drug discovery beyond the Ro5 (bRo5), it has been suggested that oral 
druggable space bRo5 may extend up to a log Poct of 6 [4].  
In addition to implementation in the Ro5, log Poct is also applied as indicators of project progresses through the 
lipophilicity efficiency (LipE) equation [5]. The concept of LipE allows medicinal chemists to normalize the 
observed potency with changes in lipophilicity and thus LipE is used in the evaluation of specific structural 
modifications during the progression of a chemical series (e.g. the development of homologues). 
Finally, increasing lipophilicity is one of the potential approaches used by many medicinal chemists to improve 
passive permeability (an example is discussed in [6]), whereas the hERG-mediated cardiovascular liability is 
traditionally avoided by lowering lipophilicity and eliminating basic amine functionality (for instance as discussed 
by Dow [7]). Lipophilicity modulation is also applied to limit metabolism issues. 
Summing up, the role of lipophilicity in determining the overall quality of drug candidates is well established and 
log Poct and log Doct are routinely used in drug discovery programs for optimization purposes. 
log Poct and IMHB 
An intramolecular hydrogen bond (IMHB) occurs when a hydrogen bond (HB) is formed between a hydrogen 
bond donor (HBD) and a hydrogen bond acceptor (HBA) that belong to the same molecule (Figure 1).  
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Figure 1. A molecule with a hydrogen donor group HBD (D-H) and a hydrogen bond acceptor group HBA (A) can 
exist in two forms A) open (extended), in which the HBA and HBD moieties are exposed and B) closed (folded), in 
which an IMHB is formed and masks the HB properties of the HBA and HBD moieties. 
 
 
Giordanetto and other researchers recently figured out the formation or disruption IMHB as one valuable 
strategy to transform molecules into drugs [8] and suggested to include IMHB considerations in drug discovery 
programs [9]. In fact, IMHB could improve cell permeability and oral bioavailability without necessarily 
decreasing solubility and binding affinity [10] [11] [12]. For practical purposes it is therefore important to find a 
descriptor (i.e. a number) which quantifies how easily a molecule can form IMHBs. 
In principle, lipophilicity in octanol/water could be used to describe the propensity of compounds to form IMHBs 
since the formation of IMHBs is expected to mask the polarity of the HBA and HBD moieties (Figure 1) and thus 
increase log Poct.  
However, log Poct is not a convenient choice to assess IMHB properties. This is revealed by a Quantitative 
Structure-Property Relationship (QSPR) where log Poct was related to a set of Volsurf+ descriptors 
(https://www.moldiscovery.com/) by a Partial Least Square (PLS) algorithm and the final model was analysed 
using the BR analysis [13]. Shortly, BR analysis shows in one picture (see Fig. 2A for the meaning of the graphs at 
a glance) the molecular features (e.g. solutes dimensions and HB properties) governing log Poct : blocks with 
positive weighting (e.g. the green block) increase log Poct (the higher, the more), whereas those with negative 
weighting indicate how much the property decreases log Poct (the lower, the less). Moreover, blocks with 
comparable positive and negative contributions are poorly relevant in the description of log Poct. From BR analysis 
one can appreciate the dominant impact of the green Size/Shape block (from here on called Size) which is the 
major limit in the use of log Poct as a tool for IMHB considerations. In fact, log Poct mostly depends on solutes’ 
dimensions rather than HB properties, the red and the blue blocks in Fig. 2A are due to HB properties and are 
small. In practice, to use log Poct to explore IMHB properties, you need to work in a pairwise fashion: the couple 
of compounds should be formed by structurally related molecules with similar size, one of them can form IMHBs 
(the sample), the other not (the control). Some examples are provided below in the Case studies section. 
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BR analysis also highlights a second limit of log Poct as a tool for IMHB considerations. Fig. 2A shows that the red 
block (HBD properties) is split in two components with opposite sign. This means that H-bond donor groups do 
not force compounds to stay in the aqueous phase but instead they support an equal partition into octanol and 
water. Therefore, the formation of an IMHB which mostly reduces HDB properties exposure does not have a 
strong impact on log Poct. 
 
Figure 2. Some examples of BR analysis output : A) log Poct [13], B) log Ptol [13] and C) ∆logPoct-tol [14]. Block name 
and color codes: size/shape (Size, green), molecular polarity (OH2, cyan), hydrophobicity (DRY, yellow), solutes’ 
hydrogen bond donor properties (O, red), solutes’ hydrogen bond acceptor properties (N1, blue), polarity 
unbalance (Others, grey). Panel C supports that ∆log Poct-tol is mostly influenced by solutes’ HBD properties (red 
block, positive sign) and it is poorly influenced by steric descriptors (green block, negative sign). More details 
about methods and datasets could be foubd in the original literature. Shortly in any paper, a QSPR model was 
obtained by relating log Poct (log Ptol and ∆logPoct-tol ) to a set of Volsuf+ descriptors by a PLS algorithm and 
interpreted using the BR analysis. 3D structures were generated by the builder implemented in VolSurf+ and the 
presence of IMHBs was neglected.  
 
 
Going beyond octanol/water and combining log Ps 
In the previous section we highlighted that log Poct is not the best tool for IMHB considerations. From BR analysis 
one could reason to replace octanol/water with a biphasic system in which the Size contribution is less important 
whereas HBD and HBA blocks are more important. Such a system could be more sensible to characterize the 
propensity of compounds to form IMHBs. 
Log Ptol, the logarithm of the partition coefficient P in the toluene/water system was recently introduced in drug 
discovery by Shalaeva and coworkers [9]. BR analysis (Fig. 2B) revealed that, if compared to log Poct, log Ptol shows 
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a major impact of the HB-related blocks (both the red and the blue blocks are larger) but not a significative 
decrease of the Size (green block) which remains the most important block. 
To limit the impact of Size, a difference between log Ps is expected to provide good results and in fact ∆log Poct-
tol (i.e. the difference between log Poct and log Ptol) is a clean descriptor of exposed HBD properties [9]. BR analysis 
supports this expectancy (Fig. 2C) showing that ∆log Poct-tol is mostly influenced by HBD solutes’ property (red 
block, positive sign) and it is poorly influenced by steric descriptors (green block, negative sign) [14]. The presence 
of IMHBs thus produces low ∆log Poct-tol values. 
Case studies 
As discussed above, the major impact of Size prevents log Poct values from providing clean information about the 
propensity of compounds to form IMHB and a trick to overpass this issue is pair analysis. This consists in 
comparing a sample with a substructure prone to IMHB formation along with a control compound with similar 
structure (and thus Size) but incapable of forming that bond. Two examples are discussed below.  
In the first example, we pay our attention on the couple of compounds 3a and 3b (Figure 3A) reported in the 
literature by Kuhn and coworkers [15]. 3b shows a substructure prone to IMHB formation whereas 3a (the 
control) is a compound incapable of forming that bond since a hydrogen atom is substituted by a more lipophilic 
methyl group. Crystallographic data supported the presence of an IMHB in 3b. Despite the presence of the 
N-methyl substituent, log Poct of 3a (0.68) is lower than log Poct of 3b (1.39). In 3b the presence of an IMHB reduces 
the polarity of the amide and the imidazole N-H and this is revealed by the increase in experimental log Poct. In 
this case log Poct is in line with NMR data and supports the presence of the IMHB. 
In the second example, we focus on compounds 1 (the sample) and 2 (the control). Their chemical structures are 
in Fig. 3B [16]. EPSA, a supercritical fluid chromatography method specifically developed for the detection of 
IMHB [17], showed that 1 forms an IMHB. The lipophilicity in octanol/water was described by ElogD, a widely 
known and validated chromatographic surrogate of log Doct [18]. ElogD is 0.9 for 1 and 0.8 for 2. These data 
suggest that two regioisomers 1 and 2 show the same lipophilicity in the octanol/water system and thus this 
evidence does not support the presence/absence of the IMHB experimentally revealed by another experimental 
approach. 
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Figure 3. Compounds taken from the literature to discuss the limits of using log Poct to describe the propensity of 
compounds to form IMHBs. 
 
 
Due to the laboriousness of the experimental measurements, log Poct values are often assessed through 
calculators. Furthermore, this option is mandatory in very early drug discovery when dealing with virtual 
structures. A plethora of both commercial and free tools can do that [19]. However, one should be aware that 
most log Poct calculators are 2D tools and thus cannot be used for investigating IMHB formation which is 
conformation-dependent. An example is provided by Bockus and coworkers who synthetized a series of cyclic 
hexapeptide diastereomers containing γ-amino acids and determined lipophilicity and permeability properties 
[20]. Two compounds c2 and c4 are in Fig. 3C and showed identical calculated log P value, 4.60 and 2.48 
respectively when MoKa (https://www.moldiscovery.com/) and Marvin Suite 
(https://chemaxon.com/products/marvin) are used, but their experimental ElogD differs by more than one 
logarithmic unity (5.7 and 6.9). This difference could be ascribed to different IMHB networks as highlighted by 
NMR studies. 
Overall, examples in Fig. 3 support BR analysis results and show that log Poct is not the most effective tool to 
predict the capacity of compounds to form IMHBs since log Poct can reveal the presence of some but not all 
IMHBs. Therefore, its application in drug discovery should be supported by additional descriptors. 
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As discussed above, BR analysis designates ∆log Poct-tol as a pure descriptor of HBD properties. Therefore, if 
∆log Poct-tol can be experimentally obtained (solubility issues can limit the determination of log Ptol), it can be used 
to predict the propensity of compounds to form IMHBs. Some examples are discussed below. 
When a compound has a single HBD group (and at least one HBA), the application of ∆log Poct-tol is 
straightforward. If ∆log Poct-tol is close to 0 then the compound has high propensity to form IMHBs since this 
means that the contribution of the red block (i.e. HBD properties) is neglected. This was recently shown by some 
of us using 1 (Figure 4A, ∆log Poct-tol = 0.10) as an example [9].  
 
Figure 4. Chemical structures of compounds discussed in the text to highlight how to interpret ∆log Poct-tol values 
A) 1 (∆log Poct-tol = 0.10, [9]) 2) B) nelfinavir (∆log Poct-tol = 0.53) and C) indinavir (∆log Poct-tol = 1.99). Red dotted 
circles highlight HBD moieties. Cyan dotted lines show the most probable IMHBs in the molecule. In 1 only one 
IMHB is possible whereas for indinavir and nelfinavir the probability of formation of different IMHBs is reported 
(see text for details).  
 
 
The interpretation of ∆log Poct-tol is more complex when more HBD groups are present in the chemical structure. 
Nelfinavir (Fig. 4B) is a protease inhibitor which shows a molecular property profile that is generally considered 
to be disadvantageous for the membrane permeability and drug absorption [21]. It is therefore important to 
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experimentally verify whether nelfinavir have propensity to form IMHBs which could modulate its ADME 
behavior. 
Using a SiriusT3 instrument (www.sirius-analytical.com) to perform standard potentiometric titrations, we 
obtained for nelfinavir a value of ∆log Poct-tol = 0.53 (pKas= 5.96, 11.97, log Poct = 4.02, log Ptol = 3.49) which 
suggests that nelfinavir has a high capacity of forming IMHBs (considering the experimental error in the measure 
of partition coefficients, a value of ∆log Poct-tol close to 0.5 could be regarded as null). Since nelfinavir has 4 HBD 
groups, conformational analysis is expected to provide further information about the effective involvement of 
the different HBD moieties in the formation of IMHBs. The conformational sampling was carried out using 
standard conformational sampling tools, generally available in most molecular modeling packages. A low 
dielectric constant (ε=2.02) was used to mimic the apolar environment provided by toluene. The percentage of 
IMHB formed by each HBD group was evaluated weighing the influence of each conformation assuming a 
Boltzmann-like distribution of the conformers population. Such a percentage could be considered a rough 
estimation of the effective participation of HBD groups to an IMHB. Fig. 4B shows that for nelfinavir a hydroxyl 
group is always involved in the formation of an IMHB both as donor (100%) and acceptor group. Moreover, both 
the amide moieties participate to IMHB formation. Overall, all HBD groups of nelfinavir are significantly involved 
in the formation of IMHBs and justify a ∆log Poct-tol value close to 0. 
Generally speaking, in the presence of more HBD groups, the experimental ∆log Poct-tol is not often equal or near 
to 0 and it is not trivial to establish a net threshold that discriminates when IMHBs are present or not. For 
example, indinavir (Fig. 4C) is another antiviral bearing four HBD groups. For indinavir, we measured ∆log Poct-tol 
= 1.99 (pKas = 3.87 and 5.68, log Poct = 2.85, log Ptol = 0.86). The significative difference in ∆log Poct-tol between 
indinavir and nelfinavir (which bears the same number and types of HBD groups) suggests that nelfinavir has a 
major capacity of forming IMHBs than indinavir. To verify whether indinavir forms IMHBs or not, conformational 
analysis was performed and showed that in indinavir (Fig. 4C), only one of the four HBD groups present in the 
molecule is involved in the formation of an IMHB (the amide moiety) as a donor group, whereas a hydroxyl group 
is involved in IMHB as an acceptor group (HBA). This example reveals that a value of ∆log Poct-tol about 2 in the 
presence of more HBD groups does not permit to exclude the formation of IMHBs and other techniques, 
experimental (e.g. NMR) or theoretical (e.g. conformational sampling), are required to confirm the hypotheses 
suggested by ∆log Poct-tol. 
Overall, these examples support that ∆log Poct-tol is a valuable tool to experimentally assess information about 
IMHB formation. In many cases, from the numerical value researchers can direct evaluate the skill of compounds 
to form IMHBs. For complex structures, standard conformational analysis can help ∆log Poct-tol interpretation. 
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Conclusions 
Despite its wide application in research programs, the potential of lipophilicity as an elucidator of structural 
properties is not fully exploited. In this paper we showed that for a more efficient use of lipophilicity in IMHB 
considerations, the determination of log Poct is not sufficient. Indeed, we need to go beyond the traditional 
octanol/water system, set-up a second system with a more apolar organic phase (i.e. toluene/water) and 
calculate ∆log Poct-tol. This latter can provide a significant amount of information about IMHB formation and be 
used in early drug discovery. 
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